Short-term administration of cytembena and cyclophosphamide to patients with gynaecological carcinoma. (Evaluation ff laboratory examinations).
D015068:17-Ketosteroids / Q000652:urine; D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000419:Albuminuria / Q000139:chemically induced; D001219:Aspartate Aminotransferases / Q000097:blood; D001772:Blood Cell Count; D001799:Blood Sedimentation; D002118:Calcium / Q000378:metabolism; D002277:Carcinoma / Q000188:drug therapy; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000009:adverse effects; D003967:Diarrhea / Q000139:chemically induced; D004715:Endometriosis / Q000188:drug therapy; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006400:Hematocrit; D006410:Hematopoiesis / Q000187:drug effects; D006454:Hemoglobins; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008111:Liver Function Tests; D008875:Middle Aged; D009088:Mucoproteins / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000188:drug therapy; D013997:Time Factors; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy; D014846:Vulvar Neoplasms / Q000188:drug therapy
D015068:17-Ketosteroids; D006454:Hemoglobins; D009088:Mucoproteins; D003520:Cyclophosphamide; D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D002118:Calcium